Wednesday, January 25, 2012
Immatics Biotechnologies GmbH, of Tuebingen, Germany, reported Phase II data showing IMA910 was able to stimulate relevant immune responses against the tumor-associated peptides (TUMAPs) in the majority of vaccinated patients with advanced and/or metastatic colorectal cancer who had shown no progression following 12 weeks of first-line oxaliplatin-based chemotherapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.